Nabriva Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nabriva Therapeutics generated cash of -$36,711,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,851,000 last year. Net change in cash is therefore -$35,297,000.
Cash Flow
| 2013 | -5.17M | 3.42M | 1.40M |
|---|---|---|---|
| 2014 | -10.53M | -80.25K | 8.78M |
| 2015 | -21.75M | -75.53M | 131.95M |
| 2016 | -49.32M | 23.35M | 22.30M |
| 2017 | -69.34M | 49.74M | 72.21M |
| 2018 | -72.72M | -4.60M | 92.92M |
| 2019 | -71.89M | 331K | 56.07M |
| 2020 | -71.33M | -274K | 26.92M |
| 2021 | -59.55M | -81K | 66.36M |
| 2022 | -36.71M | -263K | 1.85M |
NBRV Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 47.83M | 41.59M | 86.41M | 102.00M | 86.76M | 32.77M | 36.44M | 1.93M | 4.00M | 4.89M |
Operating activities | ||||||||||
Net income | -57.18M | -49.45M | -69.48M | -82.76M | -114.78M | -74.35M | -54.89M | -31.38M | -16.27M | 15.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 217K | 637K | 820K | 770K | 510K | 432K | 233K | 150.87K | 152.00K | 197.46K |
Stock-based compensation expense | 1.96M | 3.29M | 5.21M | 9.74M | 5.15M | 5.73M | 2.54M | 0 | 0 | 28.99K |
| Deferred income tax benefit | 1.96M | 3.29M | 5.21M | 9.74M | 5.15M | 5.73M | 2.54M | 0 | 0 | 28.99K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 9.01M | -8.11M | -5.88M | 2.58M | 0 | 0 | -1.93M | -3.13M | 0 | 3.62M |
Inventories | 4.83M | -8.68M | -5.14M | -682K | 0 | 0 | 5.90M | 0 | 0 | 0 |
Accounts payable | 1.09M | 1.58M | -1.81M | 1.31M | -2.96M | 2.58M | -383K | 5.95M | 644.48K | -1.61M |
Cash generated by operating activities | -36.71M | -59.55M | -71.33M | -71.89M | -72.72M | -69.34M | -49.32M | -21.75M | -10.53M | -5.17M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -115K | -30K | -57.04M | -75.37M | 0 | 0 |
Investments In Property Plant And Equipment | -211K | -25K | -113K | -61K | -229K | -1.17M | -603K | -163.99K | -82.68K | -33.14K |
Acquisitions Net | 0 | 0 | 0 | 0 | -4.26M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -263K | -81K | -274K | 331K | -4.60M | 49.74M | 23.35M | -75.53M | -80.25K | 3.42M |
Financing activities | ||||||||||
Common Stock Issued | 2.12M | 27.91M | 53.46M | 20.13M | 50M | 80M | 24.82M | 149.35M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -30M | 0 | 0 | 0 | 0 | 0 | -2.12M | -805.04K |
Cash used in financing activities | 1.85M | 66.36M | 26.92M | 56.07M | 92.92M | 72.21M | 22.30M | 131.95M | 8.78M | 1.40M |
Net Change In Cash | -35.29M | 6.24M | -44.82M | -15.59M | 15.23M | 53.99M | -3.66M | 34.66M | -1.84M | -350.74K |
Cash at end of period | 12.53M | 47.83M | 41.59M | 86.41M | 102.00M | 86.76M | 32.77M | 36.60M | 2.15M | 4.54M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |